Haas Jennifer, Franklin Andrew, Houser Matthew, Maraldo David, Mikola Mark, Ortiz Roberto, Sullivan Elizabeth, Otero José M
Merck Research Laboratories, Merck & Co., Inc, West Point, PA, United States.
Merck Research Laboratories, Merck & Co., Inc, West Point, PA, United States.
Vaccine. 2014 May 19;32(24):2927-30. doi: 10.1016/j.vaccine.2014.02.028. Epub 2014 Mar 2.
This case study provides an example of how Quality by Design (QbD) principles were applied to accelerate process development to manufacture a vaccine candidate at commercial scale. By leveraging an existing manufacturing platform process, a risk assessment was used to differentiate process parameters that could be defined using a combination of scientific and historical manufacturing knowledge from those that merited additional process characterization by experimentation. Select parameters, and their interactions, were evaluated by a Design of Experiment (DoE) series. This systematic approach required less time and fewer resources and resulted in the definition of a reliable and robust manufacturing process that meets regulatory requirements.
本案例研究提供了一个示例,展示了如何应用质量源于设计(QbD)原则来加速工艺开发,以实现商业化规模生产候选疫苗。通过利用现有的生产平台工艺,进行风险评估以区分可根据科学和历史生产知识组合来定义的工艺参数,以及那些需要通过实验进行额外工艺表征的参数。通过一系列实验设计(DoE)对选定的参数及其相互作用进行了评估。这种系统方法所需的时间和资源更少,并最终确定了一个符合监管要求的可靠且稳健的生产工艺。